noscript

News and Announcements

Innate Immunotherapeutics Gets Patent Ahead of Investor Talks

  • Published December 18, 2012 9:26PM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

Auckland, New Zealand December 18 2012: A new drug for the treatment of secondary progressive multiple sclerosis (SPMS) called MIS416, developed by New Zealand biopharmaceutical company Innate Immunotherapeutics, has been granted a patent in the United States.

Innates chief executive Simon Wilkinson says the US patent is a significant milestone as the US market represents around 70% of the worldwide MS market by revenue. He says currently there are no drugs approved to effectively treat SPMS.

—–

To view the full article, please click here.

 

Company Updates

View All
The Index Approach in Early-Stage Venture Capital: Reconsidered
Capital Insights
The Index Approach in Early-Stage Venture Capital: Reconsidered

The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]

Read more
The Future Is Now: The Evolution of Dealflow with Wholesale Investor
Capital Insights
The Future Is Now: The Evolution of Dealflow with Wholesale Investor

If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]

Read more
View All

Join over 45,000+ sophisticated investors

Join Now